S&P 500   4,348.36 (-1.22%)
DOW   34,206.11 (-0.68%)
QQQ   360.24 (-1.18%)
AAPL   174.89 (-0.34%)
MSFT   321.40 (+0.20%)
META   299.58 (-0.03%)
GOOGL   131.51 (-1.67%)
AMZN   130.48 (-3.56%)
TSLA   257.72 (-1.85%)
NVDA   413.38 (-2.13%)
NIO   8.53 (-3.29%)
BABA   84.44 (-1.52%)
AMD   96.64 (-3.69%)
T   15.34 (-1.35%)
F   12.21 (-1.21%)
MU   68.47 (-1.74%)
CGC   0.80 (-7.75%)
GE   113.70 (-1.00%)
DIS   83.08 (+0.63%)
AMC   7.81 (-4.29%)
PFE   33.01 (-1.81%)
PYPL   58.86 (-3.29%)
NFLX   385.80 (-0.13%)
S&P 500   4,348.36 (-1.22%)
DOW   34,206.11 (-0.68%)
QQQ   360.24 (-1.18%)
AAPL   174.89 (-0.34%)
MSFT   321.40 (+0.20%)
META   299.58 (-0.03%)
GOOGL   131.51 (-1.67%)
AMZN   130.48 (-3.56%)
TSLA   257.72 (-1.85%)
NVDA   413.38 (-2.13%)
NIO   8.53 (-3.29%)
BABA   84.44 (-1.52%)
AMD   96.64 (-3.69%)
T   15.34 (-1.35%)
F   12.21 (-1.21%)
MU   68.47 (-1.74%)
CGC   0.80 (-7.75%)
GE   113.70 (-1.00%)
DIS   83.08 (+0.63%)
AMC   7.81 (-4.29%)
PFE   33.01 (-1.81%)
PYPL   58.86 (-3.29%)
NFLX   385.80 (-0.13%)
S&P 500   4,348.36 (-1.22%)
DOW   34,206.11 (-0.68%)
QQQ   360.24 (-1.18%)
AAPL   174.89 (-0.34%)
MSFT   321.40 (+0.20%)
META   299.58 (-0.03%)
GOOGL   131.51 (-1.67%)
AMZN   130.48 (-3.56%)
TSLA   257.72 (-1.85%)
NVDA   413.38 (-2.13%)
NIO   8.53 (-3.29%)
BABA   84.44 (-1.52%)
AMD   96.64 (-3.69%)
T   15.34 (-1.35%)
F   12.21 (-1.21%)
MU   68.47 (-1.74%)
CGC   0.80 (-7.75%)
GE   113.70 (-1.00%)
DIS   83.08 (+0.63%)
AMC   7.81 (-4.29%)
PFE   33.01 (-1.81%)
PYPL   58.86 (-3.29%)
NFLX   385.80 (-0.13%)
S&P 500   4,348.36 (-1.22%)
DOW   34,206.11 (-0.68%)
QQQ   360.24 (-1.18%)
AAPL   174.89 (-0.34%)
MSFT   321.40 (+0.20%)
META   299.58 (-0.03%)
GOOGL   131.51 (-1.67%)
AMZN   130.48 (-3.56%)
TSLA   257.72 (-1.85%)
NVDA   413.38 (-2.13%)
NIO   8.53 (-3.29%)
BABA   84.44 (-1.52%)
AMD   96.64 (-3.69%)
T   15.34 (-1.35%)
F   12.21 (-1.21%)
MU   68.47 (-1.74%)
CGC   0.80 (-7.75%)
GE   113.70 (-1.00%)
DIS   83.08 (+0.63%)
AMC   7.81 (-4.29%)
PFE   33.01 (-1.81%)
PYPL   58.86 (-3.29%)
NFLX   385.80 (-0.13%)
NASDAQ:THTX

Theratechnologies (THTX) Stock Forecast, Price & News

$2.21
+0.07 (+3.27%)
(As of 02:11 PM ET)
Compare
Today's Range
$2.12
$2.23
50-Day Range
$0.94
$3.60
52-Week Range
$0.90
$11.06
Volume
23,321 shs
Average Volume
86,885 shs
Market Capitalization
$53.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Theratechnologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,551.4% Upside
$36.00 Price Target
Short Interest
Healthy
0.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

633rd out of 961 stocks

Pharmaceutical Preparations Industry

292nd out of 448 stocks


THTX stock logo

About Theratechnologies (NASDAQ:THTX) Stock

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

THTX Price History

THTX Stock News Headlines

Biopharma Firm Completes Reverse Stock Split
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Theratechnologies (TSX: TH)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Theratechnologies: Fiscal Q2 Earnings Snapshot
JonesTrading Sticks to Their Buy Rating for Theratechnologies (THTX)
See More Headlines
Receive THTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

THTX Company Calendar

Last Earnings
7/12/2023
Today
9/21/2023
Next Earnings (Confirmed)
9/26/2023
Fiscal Year End
11/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:THTX
Employees
144
Year Founded
1993

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+1,543.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,240,000.00
Pretax Margin
-44.44%

Debt

Sales & Book Value

Annual Sales
$80.06 million
Book Value
($0.93) per share

Miscellaneous

Free Float
N/A
Market Cap
$53.00 million
Optionable
Not Optionable
Beta
1.25

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Paul Lévesque (Age 59)
    Pres, CEO & Director
    Comp: $1.31M
  • Mr. Philippe Dubuc M.B.A. (Age 56)
    MBA, Sr. VP & CFO
    Comp: $449.76k
  • Mr. Jocelyn Lafond L.L.M. (Age 55)
    LL.B., Gen. Counsel & Corp. Sec.
    Comp: $325.86k
  • Dr. Christian Marsolais Ph.D. (Age 60)
    Sr. VP & Chief Medical Officer
    Comp: $466.81k
  • Mr. John Leasure (Age 58)
    Global Commercial Officer
    Comp: $513.95k
  • Hon. Andre Dupras M.Sc. (Age 59)
    VP of HR













THTX Stock - Frequently Asked Questions

Should I buy or sell Theratechnologies stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" THTX shares.
View THTX analyst ratings
or view top-rated stocks.

What is Theratechnologies' stock price forecast for 2023?

3 equities research analysts have issued 12-month price objectives for Theratechnologies' shares. Their THTX share price forecasts range from $36.00 to $36.00. On average, they anticipate the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 1,543.8% from the stock's current price.
View analysts price targets for THTX
or view top-rated stocks among Wall Street analysts.

How have THTX shares performed in 2023?

Theratechnologies' stock was trading at $3.5312 on January 1st, 2023. Since then, THTX stock has decreased by 38.0% and is now trading at $2.19.
View the best growth stocks for 2023 here
.

Are investors shorting Theratechnologies?

Theratechnologies saw a increase in short interest in August. As of August 31st, there was short interest totaling 83,500 shares, an increase of 126.9% from the August 15th total of 36,800 shares. Based on an average daily trading volume, of 204,300 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.4% of the company's shares are sold short.
View Theratechnologies' Short Interest
.

When is Theratechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023.
View our THTX earnings forecast
.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (NASDAQ:THTX) announced its quarterly earnings data on Wednesday, July, 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.16. The firm earned $17.55 million during the quarter.

When did Theratechnologies' stock split?

Shares of Theratechnologies reverse split on the morning of Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What guidance has Theratechnologies issued on next quarter's earnings?

Theratechnologies issued an update on its FY 2023 earnings guidance on Thursday, July, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82.00 million-$87.00 million, compared to the consensus revenue estimate of $91.66 million.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX).

What is Theratechnologies' stock symbol?

Theratechnologies trades on the NASDAQ under the ticker symbol "THTX."

Who are Theratechnologies' major shareholders?

Theratechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include National Bank of Canada FI (0.56%), Osaic Holdings Inc. (1.84%), Osaic Holdings Inc. (1.84%), Cibc World Market Inc. (1.73%), Bank of Montreal Can (0.31%) and Two Sigma Securities LLC (0.22%).

How do I buy shares of Theratechnologies?

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theratechnologies' stock price today?

One share of THTX stock can currently be purchased for approximately $2.19.

How much money does Theratechnologies make?

Theratechnologies (NASDAQ:THTX) has a market capitalization of $53.00 million and generates $80.06 million in revenue each year. The company earns $-47,240,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does Theratechnologies have?

The company employs 144 workers across the globe.

Does Theratechnologies have any subsidiaries?
The following companies are subsidiares of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.
Read More
How can I contact Theratechnologies?

Theratechnologies' mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The official website for the company is www.theratech.com. The company can be reached via phone at (514) 336-7800, via email at communications@theratech.com, or via fax at 514-331-9691.

This page (NASDAQ:THTX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -